Gene therapy shows promise in tackling X-linked RP
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Search
Search results
A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
Webinar: How your donations make a difference…in conversation with our new research grantees
Join Research Development Manager, Kate Arkell as she speaks to our latest research grantees about their projects.
Types of genetic testing
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing
Sirius clinical trial – Exon 13 mutation of USH2A
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Johnson & Johnson gene therapy update – What happens now?
The latest research news from Retina UK.
Autoimmune Retinopathy
Autoimmune diseases are quite distinct from inherited retinal dystrophies.